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Endocrine-disrupting chemicals (EDCs)
became the focus of both public and scientiﬁc
interest when defects in sexual behavior and
reproductive ability of wild-living animals
were ascribed to their steroid-like or anti-
steroid androgenic properties (Colborn et al.
1993). In the aftermath, these observations
were reproduced in many laboratory animal
models. Whether human reproduction is also
affected by the action of EDCs is currently a
topic of controversial discussion (Safe 2004;
Toppari 2002; Waring and Harris 2005).
Furthermore, there is growing evidence that,
in addition to the reproductive, other
endocrine systems such as the hypothalamus–
pituitary–thyroid (HPT) axis may be targets
of endocrine disruption. In particular, poly-
halogenated phenolic compounds such as
polychlorinated biphenyls (PCBs) and poly-
brominated diphenyl ethers (PBDEs), proba-
bly because of their structural resemblance to
thyroid hormones (Cody et al. 1986), may
cause disturbance of thyroid hormone home-
ostasis, hypothyroidism, thyroid hyperplasia,
and neoplasia (Hagmar 2003; Siddiqi et al.
2003), and developmental defects of the cen-
tral nervous system (CNS) in experimental
animals and humans (Koopman-Esseboom
et al. 1994; Meerts et al. 2004). 
It now has been shown that there may be
multiple targets for interference by various
EDCs with the complex regulatory network of
thyroid hormone synthesis, metabolism, distri-
bution, and action on the various levels of
endocrine regulation and feedback control.
These targets include thyrotropin receptor
(Auf’mkolk et al. 1985a, 1985b; Santini et al.
2003); iodide uptake by the sodium iodide
symporter (NIS; Schröder-van der Elst et al.
2004); type I 5´-deiodinase (5´DI) (Auf’mkolk
et al. 1986; Ferreira et al. 2002; Schmutzler
et al. 2004); transthyretin (TTR) (Köhrle et al.
1988; van den Berg 1990; Yamauchi et al.
2003); thyroid hormone receptor (TR)
(Bogazzi et al. 2003; Moriyama et al. 2002);
and thyroid hormone-dependent growth of
pituitary cells (Ghisari and Bonefeld-Jorgensen
2005). In the brain, PCBs may disrupt normal
differentiation regulated by thyroid hormones,
although they do not act as thyroid hormone-
like ligands (Zoeller 2005). Moreover, com-
plex biological developmental programs
controlled by thyroid hormones may be dis-
turbed by EDC action such as metamorphosis
in the amphibian Xenopus laevis (Kloas 2002).
Yet, data on EDCs affecting the HPT axis are
comparatively scarce. 
Within the CREDO (cluster of research
into endocrine disruption in Europe) Cluster,
which is part of the Sixth European Union
framework program, the EURISKED (multi-
organic risk assessment of selected endocrine
disruptors) consortium worked on a group of
projects assessing multiorganic effects of
selected endocrine disruptors. These projects
included a focus on the thyroid gland and its
target organs. In this article we summarize the
ﬁrst results. Chosen for analysis was an envi-
ronmentally and nutritionally relevant collec-
tion of substances suspected to have
endocrine-disrupting activity because of their
steroid-like or anti-steroid effects. These sub-
stances included genistein as well as glycitein
and daidzein (isoflavones from soybean);
resveratrol (phytoalexin from grapes); sily-
marin (flavonol–lignane mixture from the
milk thistle); xanthohumol (XN; prenylated
chalcone from hops, Humulus lupulus L.);
8-prenylnaringenin (8-PN; prenylated
ﬂavonone from hops); benzophenone-2, ben-
zophenone-3, 4-methylbenzylidene camphor,
and octyl-methoxycinnamate [BP2, BP3,
OMC, 4-MBC, respectively; ultraviolet (UV)
filters]; F21388 (synthetic, halogenated
ﬂavonoid); 4-nonylphenol (4-NP; e.g., emul-
gator); bisphenol A (BPA; building block for,
e.g., polycarbonate plastics); dibutylphthalate
(e.g., plasticizer); linuron and procymidon
(pesticides); 5α-androstane-3β,17β-diol
[adiol; proposed to be an endogenous ligand
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BACKGROUND: There is growing evidence that, in addition to the reproductive system, the
hypothalamic–pituitary–thyroid axis is a target of endocrine-disrupting compounds (EDCs).
However, this is not reflected adequately in current screening and assessment procedures for
endocrine activity that to date determine only general parameters of thyroid function. 
OBJECTIVE AND METHODS: We used several in vitro and ex vivo assays in an attempt to identify
suitable biomarkers for antithyroid action testing a selected panel of putative EDCs. 
RESULTS: In vitro we detected stimulation or inhibition of iodide uptake into FRTL-5 rat thyroid
cells, inhibition of thyroid hormone binding to transthyretin, agonistic or antagonistic effects in a
thyroid hormone receptor–dependent reporter assay, and inhibition of thyroid peroxidase using a
novel assay system based on human recombinant thyroperoxidase that might be suitable for routine
screening for potential EDCs. In rats, chronic application of several EDCs led to changes in thyroid
morphology, alterations of thyrotropin and thyroid hormone serum levels as well as alterations in
peripheral thyroid hormone–regulated end points such as malic enzyme and type I 5´-deiodinase
activity. 
CONCLUSIONS: As the effects of EDCs do not reflect classic mechanisms of hormone-dependent
regulation and feedback, we believe multitarget and multimodal actions of EDCs affect the hypo-
thalamic–pituitary–thyroid axis. These complex effects require a diverse approach for screening,
evaluation, and risk assessment of potential antithyroid compounds. This approach involves novel
in vitro or cell-based screening assays in order to assess thyroid hormone synthesis, transport,
metabolism, and action as well as in vivo assays to measure thyroid hormone–regulated tissue-
speciﬁc and developmental end points in animals. 
KEY WORDS: deiodinase, flavonoids, malic enzyme, pituitary, sodium iodide symporter, thyroid
gland, thyroid peroxidase, transthyretin, UV ﬁlters. Environ Health Perspect 115(suppl 1):77–83
(2007). doi:10.1289/ehp.9369 available via http://dx.doi.org/ [Online 8 June 2007]of estrogen receptor β (ER-β)] and 17β-estra-
diol benzoate (E2). We show that several of
these substances also interfere with multiple
targets at various levels of the HPT axis in a
tissue-speciﬁc manner. These targets included
weight and morphology of the thyroid gland,
iodide uptake by the NIS, iodide organiﬁca-
tion by thyroid peroxidase (TPO), binding of
the thyroid hormone thyroxine (T4) to TTR,
the metabolism of thyroid hormones by deio-
dinases, and the action of the biologically
active thyroid hormone triiodothyronine (T3)
mediated by TRs functioning as ligand-
dependent transcription factors.
Current Protocols for Assessing
Effects on the HPT Axis
Assays currently being used to address thy-
roid-disrupting effects were developed from
existing protocols for detecting general toxico-
logic effects of substances. These assays mea-
sure biochemical, clinical, hematologic,
histologic, neurologic, behavioral, reproduc-
tive, and developmental end points. To
address thyroid toxicity, the ability to deter-
mine several thyroid-relevant parameters was
incorporated into these tests. Examples are
the male and female pubertal assays as devel-
oped by the U.S. Environmental Protection
Agency [Endocrine Disruptor Screening and
Testing Advisory Committee (EDSTAC)
1998] and the enhanced Organisation for
Economic Co-operation and Development
(OECD) Test Guideline 407 (Gelbke et al.
2004). Currently, end points describing thy-
roid function, that is, serum T4, T3, and thy-
rotropin (TSH) as well as thyroid weight and
histology, are being assessed according to
these protocols. 
An amphibian assay (XEMA) based on
the T3-dependent metamorphosis of tadpoles
using the model X. laevis has been developed
and is now being validated (Degitz et al.
2005; Opitz et al. 2006). This assay examines,
for example, tail resorption, forelimb emer-
gence, histologic alterations in the thyroid
gland, and TSH expression. No sufficiently
developed assay or standardized, validated
protocol exists for the assessment of thyroid
function in birds or ﬁsh nor is there any func-
tional in vitro screening test for antithyroid
action. Whether EDCs affect thyroid hor-
mone economy and action in invertebrates,
which do not have thyroid tissue organized as
a gland composed of follicles (amphibians,
birds, mammals) or at least single thyroid
hormone–producing follicles (fish), has not
been determined. An extensive overview of
testing protocols used to determine thyroid
toxicants is published by the OECD
Environment Directorate and is available on
the OECD website (BATTELLE 2006).
In Vitro Assays
Iodide uptake. Iodide accumulation in the
epithelial cells of the thyroid gland, the thyro-
cytes, is the first step in thyroid hormone
biosynthesis. This process is catalyzed by the
NIS, a member of the SGLT-1 (sodium glu-
cose cotransporter type 1) family of sodium-
dependent transporters. By coupling the
transport of iodide against its gradient to the
inﬂux of sodium along its gradient across the
cytoplasmic membrane of the thyrocyte, NIS
concentrates the trace element iodide by a fac-
tor of up to 50-fold compared with serum
levels (Dohan et al. 2003).
The inﬂuence of EDCs on iodide uptake
(Table 1) was analyzed in FRTL-5 cells, a
model of normal, nontransformed rat thyro-
cytes (Weiss et al. 1984). One compound
tested was xanthohumol (XN/ Radovic et al.
2005). A time-dependent stimulation of
iodide uptake by NIS was observed with
nanomolar concentrations of XN. Acute
treatment did not have any effect; however, a
rise in iodide accumulation was observed after
2 and 3 days of culture in the presence of XN.
The increase was maximal (about 50% com-
pared with the untreated control) after 3 days
of stimulation with 1 nM XN. Northern blot
analysis did not reveal any difference in NIS
mRNA transcript levels between control cells
and those treated with 0.1 nM–1 µM XN for
3 days, indicating that posttranscriptional
events are probably responsible for the effects.
Alternatively, there may also be an inﬂuence
on “auxiliary” proteins such as Na+/K+-
ATPase, which is responsible for building up
the sodium gradient across the thyrocyte
membrane. Recently it was reported that sev-
eral dialkyl phthalates both increase iodide
uptake and stimulate NIS promoter activity
in FRTL-5 cells (Breous et al. 2005; Wenzel
et al. 2005).
In contrast, the soy isoflavone genistein
decreased iodide accumulation. After 5 days
of incubation with 10 µM genistein, iodide
uptake into FTRL-5 cells was reduced to
52% of the untreated control. Iodide uptake
was also inhibited, by the UV filters OMC
and 4-MBC at concentrations of 0.1 and
1.0 µmol/L and by 4-NP at 10 µmol/L after
5 days in the presence of these EDCs
(Schmutzler et al. 2006). No acute effects
were observed for any of the substances.
Interestingly, in vivo administration of low
doses of 4-MBC (7–47 mg/kg body weight/
day) caused goiter in the treated rats as well as
in the F1 generation of their offspring
(Schlumpf et al. 2004). If this is indeed a con-
sequence of reduced thyroid hormone synthe-
sis due to lower iodide availability, this must
be clariﬁed in future investigations. 
Together, these results indicate that expo-
sure of rat thyrocytes to EDCs in nanomolar
to micromolar concentrations may either
increase or decrease iodide uptake by NIS
after one or two cell cycles, whereas in our
experiments, no acute effects were observed. 
Iodide organification. The heme protein
TPO plays a central role during thyroid hor-
mone synthesis, as it catalyzes all the essential
steps involved in this process (Taurog 2005).
The oxidation of iodide, the iodination of tyro-
syl residues of thyroglobulin (Tg), and the cou-
pling of two iodotyrosyls to give Tg-coupled
thyroid hormones T4 and T3 which, after
hydrolysis, are released by the thyroid gland in
response to an appropriate stimulus by the
pituitary hormone TSH. Hydrogen peroxide
(H2O2), generated by the thyrooxidase
enzymes ThOX1 and ThOX2, is an essential
cosubstrate in this reaction sequence because it
serves as a source for oxidative equivalents.
TPO is a target for the inhibiting activity of
propylthiouracil (PTU) and methimazole
(MMI), currently the only antithyroid drugs
with known therapeutic relevance for the
treatment of hyperthyroidism (Cooper 2005).
TPO also seems to be the target of goitrogens
from nutritive sources such as the isoflavone
Schmutzler et al.
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Table 1. Effects of selected EDC tested in thyroid-relevant in vitro assays.
Compound Iodide uptake TPO activity TR agonist TR antagonist T4 binding to TTR
4-MBC ↓ —N DN DN D
4-NP  ↓↓↑↓ ND
Adiol  ↓ —N DN DN D
BPA — ↓ ND ND ND
BP2 — ↓↑—N D
BP3 — — ↑ —N D
Daidzein ND ND ND ND ↓
Dibutylphthalate — — ND  ND  ND
E2 ↓ —N DN DN D
F21388 ND ↓ ND ND ND
Genistein  ↓↓↑— ↓
Glycitein ND ND ND ND ↓
Linuron — — ↑ —N D
OMC  ↓ — ↑ —N D
Procymidon — — ND ND ND
Resveratrol — ↓↑—N D
Silymarin — ↓↑—N D
Xanthohumol  ↑ —N DN DN D
Abbreviations: ↑, stimulatory or agonistic effect; ↓, inhibitory or antagonistic effect; —, no effect; ND, not determined.genistein from soybeans or related environ-
mental or nutritional ﬂavonoids (Cody et al.
1986). It was already known more than four
decades ago that feeding infants with soy milk
caused goiter in those with inadequate iodine
(Hydovitz 1960; Shepard et al. 1960; Van
Wyk et al. 1959). As demonstrated later,
genistein, an isoflavone component of soy,
could be responsible for the pathogenesis of
this type of childhood goiter, as this com-
pound, well known for its endocrine activity
exerted via interaction with estrogen and other
nuclear receptors (Cos et al. 2003; Divi et al.
1997; Ricketts et al. 2005), also inhibits TPO
in vitro and in vivo (Chang and Doerge 2000). 
We therefore looked for the effects of
other suspected EDCs on TPO (Table 1)
using as a source for enzyme activity FTC-238
human thyroid carcinoma cells stably trans-
fected with an expression clone coding for
human recombinant (hr) TPO (data not
shown). Functional hrTPO was prepared by
digitonin extraction of the cell membranes
and used in the guaiacol oxidation assay
(Hosoya 1963), a classic test for the determi-
nation of peroxidase activities. In this system,
several suspected EDCs from plant sources
inhibited TPO activity, namely genistein
(used as a positive control), but also resvera-
trol, silymarin, and the synthetic flavonoid
F21388. Furthermore, the industrial chemi-
cals 4-NP and BPA also inhibited TPO. IC50
(median inhibitory concentration) values
ranged from 0.83 to 174 µmol/L. 4-MBC,
OMC, procymidon, linuron, BP3, 4-NP, E2,
and adiol had no effect. As reported for genis-
tein (Divi et al. 1997), preincubation of TPO
in the presence of BP2 or F21388 in combina-
tion with H2O2, but without the substrate
guaiacol, inactivated TPO. This effect, how-
ever, was prevented by adequate (micromolar)
concentrations of iodide in the preincubation
mixture. BP2-treated rats exhibited decreased
T4 and increased TSH serum levels (Jarry
et al. 2004). These results indicate that the
inhibitory effects of EDCs on TPO may add
to and aggravate the consequences of an inade-
quate iodide supply (Schmutzler et al. 2006). 
TR-mediated transcriptional activation.
To assess interference with the action of thy-
roid hormone receptors, an in vitro reporter
system was established to screen for the bind-
ing and transcriptional activity of EDCs. A
duplicated thyroid hormone response element
of the DR4 type was cloned into the luciferase
vector pGL3 upstream of a SV40 promoter.
This construct responded to T3 with a
> 50-fold induction of luciferase activity and
an EC50 (median effective concentration)
value of 1.0 nmol/L in the human hepatocar-
cinoma cell line HepG2. Our data indicate
that BP2, BP3, genistein, resveratrol, sily-
marin, linuron, OMC, and 4-NP behave as
TR agonists in this reporter assay. 4-NP also
displayed antagonistic activity if co-applied
with 1 nM T3 (Table 1). In our experiments,
TR-agonistic or -antagonistic effects are
observed at rather high micromolar concentra-
tions compared with those of the natural lig-
and T3 acting at picomolar or nanomolar
concentrations. Whether they have any physi-
ologic or pathophysiologic relevance must be
tested in vivo in animal models.
Thyroid hormone distribution. There are
three thyroid hormone binding proteins in
human plasma: albumin, with high capacity
and low affinity; thyroxine-binding globulin
(TBG), with low capacity and high affinity;
and TTR with an intermediate capacity and
affinity (Köhrle 2000). T4 binding to these
distributor proteins, especially to TTR, is
known to be highly sensitive for interference
by polyhalogenated phenolic compounds or
by synthetic flavonoids (Köhrle et al. 1988;
van den Berg 1990; Yamauchi et al. 2003).
Therefore, the inﬂuence of soy isoﬂavones on
T4 binding to these three distribution pro-
teins was analyzed by nondenaturing poly-
acrylamide gel electrophoresis direct and
binding assays using purified TTR (Radovic
et al. 2006). Soy flavonoids competed with
thyroid hormone binding to TTR (Table 1)
but not to albumin and TBG. Complete dis-
placement of [125I]T4 binding to TTR was
observed in human serum incubated with
> 10 µM genistein; interference started at
approximately 0.1 µM genistein. Glycitein
showed decreased and daidzein the lowest dis-
placement potency compared with genistein.
[125I]T4 was displaced to albumin in rat and
to TBG in human serum. Soy isoﬂavones also
obstruct [125I]T4 binding to TTR in human
cerebrospinal ﬂuid. IC50 values were 0.07 µM
for genistein, 0.2 µM for glycitein, and
1.8 µM for daidzein. Thus, isoﬂavones might
alter free thyroid hormone concentrations,
resulting in altered tissue availability, metabo-
lism, renal excretion (Schröder-van der Elst
et al. 2003), and, as a consequence, disturbed
feedback to the pituitary. 
Ex Vivo Assays
Animals. Female Sprague-Dawley rats
(Winkelmann, Borchen, Germany) were
ovariectomized at 14 weeks of age and after-
wards treated for 12 weeks by oral applica-
tion of the following compounds in a
specially prepared rat chow (n = 8–11 ani-
mals/group): 2.5 or 12.5 g/kg OMC, 2.5 or
12.5 g/kg 4-MBC, 20 or 80 mg/kg 4-NP,
150 mg/kg adiol and 34.2 mg/kg E2 as a pos-
itive control. Because soy and particularly its
flavonoid compound genistein have a major
effect on thyroid function, food completely
free from soy was compared with food con-
taining soy, alone or in combination with
EDC (12.5 g/kg OMC, 12.5 g/kg 4-MBC,
80 mg/kg 4-NP, 150 mg/kg adiol and
34.2 mg/kg E2). In a second feeding experi-
ment, animals were fed 0.1 or 1 g/kg genis-
tein, 84 or 840 mg/kg resveratrol, 0.126 or
1.26 g/kg 8-PN, 75 or 300 mg/kg adiol and
4.3 and 17.3 mg/kg E2. After the treatment,
animals were sacriﬁced; organs were removed
and frozen in liquid nitrogen and kept at
–80°C until use. The animals were treated
humanely and with regard for alleviation of
suffering, and all studies have been approved
by the local University Ethical Committee.
Histology and serum hormone levels. From
feeding experiment 1, a small number of thy-
roid samples (n = 2–3/treatment group) were
examined histologically. In the 4-NP–treated
animals, a signiﬁcant decrease in the volume of
epithelial compartments resulted in a decrease
of the epithelium versus colloid ratio by about
50% (Table 2). We observed effects at both
high and low concentrations compared with
those of untreated control. 4-NP-treated ani-
mals showed a significant increase in both
serum T3 and T4 levels; however, TSH was not
decreased as might have been expected from
the morphologic data. The other animals
showed no signiﬁcant alterations in the mor-
phology of their thyroid glands. 
In the 4-MBC-treated animals, T4 serum
levels were significantly decreased without
Endocrine disruptors and thyroid hormone axis
Environmental Health Perspectives • VOLUME 115 | SUPPLEMENT 1 | December 2007 79
Table 2. Effects of selected EDCs tested in female ovariectomized rats.
ME 5´DI
Compound Histology tT4 tT3 TSH Liver Kidney Liver Kidney
E2 —— — — ↑ — ↓↑
Adiol — — — — ↑↑— ↑
4-Nonylphenol  ⇑↑ ↑ —— ———
OMC — ↓ —— — ↑↓↓
4-MBC — ↓↑↑ —— — ↓
Genistein ND ↑ ——↓ ——↑
8-PN ND — ↑ — ↓ ———
Resveratrol ND — ↑ — ↓ ——↑
Soy — ↓ ——↓ ——↑
Soy + E2 —— — — ↑↑ ↓ ↑
Soy + 4-nonylphenol — ↓ —— — — —↑
Soy + OMC — ↓ ——↑ — ↓↓
Soy + 4-MBC — ↓↓—— ——↓
Abbreviations: ⇑, 50% increase in epithelium vs. colloid ratio; ↑, stimulation; ↓, inhibition; —, no or insignificant effect;
ND, not determined; tT3 and tT4, total T3 and T4, respectively.parallel alterations in T3 levels, and TSH was
signiﬁcantly increased. This is a combination
of symptoms characteristic for a hypothyroid
condition. In rats, administration of low
doses of 4-MBC caused goiter in the treated
rats and in the F1 generation of their offspring
(Schlumpf et al. 2004). If this is a conse-
quence of reduced thyroid hormone synthesis
due to lower iodide availability, this must be
clarified in future investigations. This might
be a consequence of the inhibition of iodide
uptake via the NIS as mentioned above,
which is compatible with a well-known
increase of the T3/T4 ratio in the serum of
individuals with inadequate iodine. 
In the OMC-treated rats, T4 was also
decreased, but there was no signiﬁcant alter-
ation in T3 or in TSH levels. In the animals
fed soy-containing chow, T4 levels were
reduced compared with those of untreated
controls. This might be due to the inhibitory
action of genistein and other soy isoflavones
on TPO activity. Changes in T3 and TSH
levels were not signiﬁcant. In feeding experi-
ment 2, total serum T3 was significantly
increased by both low and high concentra-
tions of 8-PN and resveratrol (1.5- and
1.3-fold, respectively). Only small and non-
significant alterations in serum TSH were
observed. As for total T4 levels, only the
1.15-fold increase elicited by the high genis-
tein concentration was signiﬁcant. This repre-
sents a certain contradiction to feeding
experiment 1, where soy-containing chow led
to a decrease in total serum T4. On the other
hand, this is in line with data published by
Chang and Doerge (2000), who did not
observe hypothyroid effects in genistein-
treated rats. Also, one has to consider that
genistein alone might not be able to mimic all
the effects exerted by the various components
contained in soy food, as soy also contains
other antithyroid isoflavones (glycitein and
daidzein) in addition to genistein. Further-
more, soy proteins were reported to have
metabolic as well as endocrine effects, proba-
bly including the thyroid gland, although it
has not been determined if these effects are
caused by nonprotein compounds present in
the soy protein isolates (Badger et al. 2001;
Goldin et al. 2005; Messina and Redmond
2006; Zhuo et al. 2004). 
Malic enzyme. One of the best-characterized
thyroid hormone-regulated end points is malic
enzyme (ME). This protein is expressed at
high levels in the liver and is involved in lipid
metabolism by providing NADPH for fatty
acid biosynthesis (Mariash et al. 1981). In the
livers of T3-treated versus untreated rats, ME
mRNA levels were stimulated 15.5-fold and
enzyme activities 10.3-fold. In other organs,
T3-triggered stimulation was less pronounced;
the increases in mRNA levels and enzyme
activities were 1.7- and 2.6-fold in the heart
and 1.7- and 3.4-fold in the kidney, respec-
tively (Dozin et al. 1985). T3-responsive
elements were characterized in the ME pro-
moters of several vertebrate species, including
rat and human (Gonzalez-Manchon et al.
1997; Petty et al. 1990). We thus tested if ME
may be used as an appropriate marker for
thyroid hormone–disrupting action.
For the rats examined in feeding experi-
ment 1 described above, basal ME activities
were highest in the heart (18.3 µmol
NADPH generated per minute and per mil-
ligram extract protein) compared with the
liver (10.4 µmol NADPH) and the kidney
(5.9 µmol NADPH). Among the EDCs
tested, 4-NP, OMC, and 4-MBC slightly
increased ME activity in the liver up to
1.2-fold, although these differences were not
significant. The increases of about 1.5- to
2-fold triggered by E2, adiol, E2 plus soy, and
OMC plus soy, however, were significant.
Only slight differences (up to 1.25-fold) were
observed in the kidney; however, they were
signiﬁcant in the case of adiol, OMC, and E2
plus soy (Kovacs et al. 2004; Schmutzler et al.
2004). In feeding experiment 2, liver ME
activity was signiﬁcantly reduced by genistein,
resveratrol, and 8-PN to 76–50% of control
values; in kidney, only minimal and non-
signiﬁcant alterations were observed. A com-
plete overview over all observed changes in
ME activities is given in Table 2.
The most prominent and significant
change in ME activity, a 2.3-fold increase,
was elicited by E2, accompanied by an 8-fold
increase in mRNA levels as determined by
real-time polymerase chain reaction (PCR)
(Kovacs et al. 2004). On the other hand, ME
enzyme activities did not correlate with
serum T4 levels in the EDC-treated rats. This
demonstrates a disadvantage of ME as a bio-
marker for HPT axis disruption. Although it
is one of the best-characterized metabolic end
points of T3 in the liver, there is also
E2-dependent regulation of lipid metabolism,
including the activity of ME (Cho and Park
1990; Sissan and Leelamma 1996). This dual
responsiveness does not allow discrimination
between a possible estrogenic and a T3-ago-
nistic action of an EDC under investigation.
Although this may be without consequences
for the general classiﬁcation of a substance as
an EDC that disrupts metabolic end points
of hormonal regulation, it may complicate
clarifying its mechanism of action with the
aim to design other chemicals as adequate
substitutes without endocrine-disrupting
properties.
Type I 5´-deiodinase. Three deiodinase
isoenzymes are involved in thyroid hormone
metabolism. Type II 5´-deiodinase activates
the “precursor” T4 to the biologically active
T3 by removing an iodide atom from the 5´
position or the “outer ring,” whereas type III
5-deiodinase has an inactivating function as it
removes iodide from the 5 position or the
“inner ring.” Type I 5´-deiodinase can cat-
alyze both of these steps. Hepatic 5´DI is
another well-characterized T3-regulated end
point in the liver. The enzyme is stimulated
by T3 and a high carbohydrate diet (Köhrle
2002), and thyroid hormone responsive ele-
ments have been described in the 5´ regula-
tory region of the 5´DI gene (Jakobs et al.
1997; Toyoda et al. 1995). Furthermore, vari-
ous xenobiotics are known to inhibit hepatic
5´DI activity (Auf’mkolk et al. 1986; Ferreira
et al. 2002).
In EDC-treated rats from feeding experi-
ment 1, 5´DI activity was significantly
reduced by E2 and OMC, both alone and in
combination with soy-containing food,
whereas adiol and 4-MBC also caused a small
but insignificant reduction in 5´DI activity
(Schmutzler et al. 2004). In feeding experi-
ment 2, genistein and resveratrol induced
increases in liver 5´DI activity of about 33
and 59%, whereas 8-PN reduced enzyme
activity by 24%; however, none of these
changes was signiﬁcant.
In the kidney (Hamann et al. 2005), there
was a signiﬁcant increase in 5´DI activity trig-
gered by E2 (about 1.5-fold) in contrast to the
liver. OMC and 4-MBC both reduced 5´DI
activity signiﬁcantly (to < 50%). Whereas in
the liver the action of OMC and 4-MBC
might be interpreted as E2-like, this is not the
case in the kidney, as effects occur in the
opposite direction. Some of these ﬁndings are
compatible with the sex-speciﬁc difference of
hepatic 5´DI activity, which is higher in male
than in female rats (Miyashita et al. 1995;
Ogawa et al. 1999). It must also be consid-
ered that the accessibility for EDCs may vary
in different tissues and cell types. For a sum-
mary of these and other changes in 5´DI
activities triggered by the various EDC, see
Table 2.
Parameters of Thyroid
Hormone Action in the Heart
As the heart is the organ that shows the most
sensitive reaction to a hyperthyroid status, we
determined several thyroid hormone–
regulated end points in this organ using
hearts of rats from feeding experiment 1.
Effects on ME activity were small, with the
only significant difference being an approxi-
mately 16% reduction in the animals fed with
soy-containing food compared with the
control (Schmutzler et al. 2004). We also
determined the expression of the thyroid hor-
mone–regulated genes coding for myosin
heavy chain α and β and glycerol-3-phos-
phate dehydrogenase α by real-time PCR.
However, no effect was detected, indicating
that there are no thyromimetic effects of these
substances tested in feeding experiment 1
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concentrations. 
EDCs and Iodine Deﬁciency 
The essential trace element iodine plays a
central role as a constituent of the thyroid
hormones T4 and its hormonally active form
T3, which controls many aspects of vertebrate
physiology, including growth, especially of
the skeleton, differentiation and maturation
of the central nervous system as well as energy
and lipid metabolism, thermoregulation, and
heart rate and output. Iodine deficiency and
consequent deficiency in thyroid hormones
result in goiter. If this shortage is severe dur-
ing development, this may lead to critical
growth defects combined with mental retar-
dation known as cretinism. However, mild or
moderate iodine shortage causes signiﬁcantly
lower intelligence quotient values in school
children (Santiago-Fernandez et al. 2004;
Vermiglio et al. 2004). 
According to data from the World Health
Organization, in 1999, 30% of the world’s
population was at risk of iodine deficiency
disorders; 740 million people suffered from
goiter; 43 million people had iodine defi-
ciency disorder–related brain damage and
mental retardation, and 5.7 million patients
were afflicted by cretinism (International
Council for the Control of Iodine Deﬁciency
Disorders 1999). Iodine deﬁciency is not nec-
essarily a result of malnutrition found in
developing countries but may occur also in
industrial countries such as Germany
(Andersson et al. 2005). Certain risk groups
show a greater tendency to suffer from the
consequences of an insufﬁcient iodine supply,
including pregnant and breastfeeding women
(Ares et al. 2005; Darcan and Goksen 2003),
as well as vegans and vegetarians (Borak 2005;
Krajcovicova-Kudlackova et al. 2003). 
There is evidence for a mutual enhance-
ment of the effects of iodine deficiency and
nutritional or environmental goitrogens. Use
of soy milk in the diet can lead to the devel-
opment of (reversible) goiter in iodine-
deﬁcient children, probably via the inhibition
of TPO by genistein (Hydovitz 1960; Van
Wyk et al. 1959). Tobacco smoke contains
several goitrogenic substances, among them
cyanide, which is metabolized to thiocyanate,
a potent inhibitor of the NIS. Smoking, as
well as increased thiocyanate levels, is associ-
ated with an increased thyroid volume; with a
higher risk for goiter development (Brauer
et al. 2006; Galanti et al. 2005; Völzke et al.
2005); with higher prevalence, increased
severity, and poorer outcome of Hashimoto’s
thyroiditis; and with a higher prevalence of
thyroid multinodularity (Ericsson and
Lindgarde 1991; Knudsen et al. 2002).
Additional sources for goitrogenic cyanide
may be industrial pollution (Brauer et al.
2006) or consumption of cyanogenic vegeta-
bles (Biassoni et al. 1998; Chandra et al.
2004; Laurberg et al. 2002). 
These literature data suggest that an
increased burden of EDCs with effects on the
HPT axis might, similar to goitrogens, aggra-
vate adverse effects of inadequate iodine
supply or exacerbate thyroid disease status.
Summary and Conclusions
Our results, which are summarized in
Tables 1 and 2, show that the HPT axis is a
relevant target of EDC action, which has to
be considered in forthcoming screening and
assessment protocols that test for endocrine
activity. Furthermore, effects of EDCs on the
HPT axis must be considered in connection
with special dependency of the thyroid gland
on the essential trace element iodine. There
may be an enormous capacity of the thyroid
gland to adapt to adverse effects of EDCs, but
probably only as long as the iodine supply is
adequate. If this is not the case, as iodine deﬁ-
ciency still occurs in many parts of the world,
a further challenge by EDCs in addition to
their own effects may unmask or aggravate
effects elicited by iodine deﬁciency.
We detected interference by EDCs on
several levels of the HPT axis. However, they
did not conform to classic “textbook” mecha-
nisms of endocrine regulation and feedback.
a) Hormone levels did not show “concerted”
alterations, that is, lower T4 was not always
accompanied by higher TSH, for example, in
the case of 4-NP and OMC. b) Activities of
T3-sensitive enzymes did not always correlate
with concentrations of circulating thyroid
hormone levels, as although 4-NP-treatment
increased T4 levels, there was no parallel
increase in 5´DI or ME activity in the liver
or in the kidney of treated rats. Although
total T4 serum levels did not change sig-
nificantly and total T3 levels were even
increased, ME activity was reduced by up to
59% and 5´DI activity was slightly but non-
significantly decreased by resveratrol in the
liver. c) Thyroid histology did not necessarily
reﬂect hormone levels, as only effects of 4-NP
on morphology were observed, although
4-MBC also altered T4 levels. d) Furthermore,
biomarkers such as ME and 5´DI reacted to
EDC action with tissue-speciﬁc effects. Thus,
thyroid function, thyroid hormone action in
the periphery, and feedback regulation could
be disrupted at the same time and effects
would occurr in an organ-specific manner.
The reason for this disruption, apart from a
different availability of certain EDCs to the
various tissues, might be that one compound
affects more than one target in the HPT axis
or even more than one endocrine axis. A
striking example is genistein, which on one
hand inhibits TPO enzyme activity and thy-
roid hormone binding to TTR and on the
other hand also displays estrogenic and anti-
estrogenic effects by interacting with ERβ.
Additionally, estrogenic action of a com-
pound may enhance or mask an antithyroid
action. Taken together, there seems to be syn-
ergistic as well as antagonistic interference at
several levels of thyroid hormone synthesis,
action, and regulation.
These complex actions also imply that
current testing protocols may not be ade-
quate, as they focus on parameters of thyroid
function such as serum TSH, T4, and T3 as
well as thyroid weight and morphology
(EDSTAC 1998; Gelbke et al. 2004).
Assessment of the function of thyroid hor-
mones and their availability to organs, consid-
ering cell type- and tissue-specific effects, is
also required. Our data on TPO-inhibition
by certain EDCs strongly suggest that sub-
stances that are easily oxidized will inhibit
TPO and should, therefore, be tested accord-
ingly. Given the strong effect of thyroid hor-
mones on growth and development, especially
on the differentiation and maturation of the
central nervous system, developmental end
points also should be included. This inclusion
is further stressed by the recent finding that
EDCs can act in a transgenerational manner
by epigenetic modification of genes (Anway
et al. 2005). Furthermore, as shown for
body weight regulation and obesity but might
also apply to other endocrine axes, the set
points for endocrine axes are modulated by
the maternal “environment” of the fetus
(Plagemann 2005); this process could be dis-
turbed by the inﬂuence of EDCs. Thus, novel
assays that evaluate tissue and cell typical bio-
markers of thyroid hormone and EDC action
in development and maintenance of healthy
organisms are urgently needed. Our data sug-
gest some possibilities, and future experiments
will show if they can be developed into sensi-
tive, signiﬁcant, robust and efﬁcient screening
and risk assessment assays.
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